In this study, neither multisystem clinical manifestations of TSC (brain, heart, skin, eyes, kidney, lung, and liver) nor the TSC1/TSC2 gene mutation type was associated with poor QOL. This evidence concerns the gene TSC2 and tuberous sclerosis.